Clinical Trial Update: A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 study evaluating recombinant human C1 esterase inhibitor for hereditary angioedema prophylaxis has completed. Results were posted December 8, 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Ruconest (conestat alfa)

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Hereditary Angioedema | Phase 2 | Status: COMPLETED | Results posted: 2017-12-08